Meningococcal infection is a bacterial infection caused by Neisseria meningitidis, also known as meningococcus, a gram-negative bacterium. Twelve types of N. meningitides, called serogroups, have been identified, six of which (A, B, C, W, X and Y) can cause epidemics. Meningococcal meningitis is a serious infection of the thin lining that surrounds the brain and spinal cord. It can lead to death within 24 hours, and for survivors, can result in life-altering, significant long-term disabilities. A rise in morbidity and mortality of related to meningococcal infection among vast populations has made it a global concern. According to statistics published by the World Health Organization in 2017, the geographic distribution and epidemic potential of the infection differ according to the serogroup. There are no reliable estimates of the global meningococcal disease burden due to inadequate surveillance in several parts of the world.
As per the Centers for Disease Control and Prevention, in 2015, about 375 total cases of meningococcal disease were reported (incidence rate of 0.18 cases per 100,000 persons). The rates of the disease are highest in children younger than one year, followed by a second peak in adolescence. In recent years, the effective implementation of several targeted vaccination programs through massive campaigns in various countries, especially sub-Saharan Africa, has significantly reduced the burden of meningococcal disease. Technological advances in vaccinology have further improved the efficacy of vaccines, leading to key public health accomplishments. Increased government initiatives and funding for R&D activities & newer treatment and infection control in healthcare settings is also a key factors driving the market globally.
The global meningococcal infections treatment market can be segmented based on type, end-user, distribution channel, and region. In terms of type, the global market can be categorized into vaccination and chemoprophylaxis. The vaccination segment can be further bifurcated into polysaccharide vaccines, meningococcal conjugate vaccines, and protein-based vaccines. Based on end-user, the global meningococcal infections treatment market can be bifurcated into adults and children. The children segment is expected to expand at a faster rate because bacterial meningitis mostly affects children. Increase in the incidence of meningitis in children is one of the major factors fueling the global meningococcal infections treatment market. Moreover, risk of permanent disabilities among children and rise in awareness about proper dose of immunization are projected to drive the meningococcal infections treatment market. However, bacterial resistance to penicillin and lack of access to vaccine approval are likely to hamper the meningococcal infections treatment market in the next few years. Based on distribution channel, the global meningococcal infections treatments market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is likely to expand at a significant pace during the forecast period as several types of vaccine are widely available in hospital pharmacies.
In terms of region, the global meningococcal infections treatment market can be segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Mexico, Brazil, and Rest of Latin America), and Middle East & Africa (Saudi Arabia, South Africa, Israel, and Rest of Middle East and Africa). North America dominates the global meningococcal infections treatment market. The region is projected to account for a significant share of the global meningococcal infections treatment market during the forecast period, due to the presence of key vaccine manufacturers and awareness about immunization. Favorable government support in terms of inclusion of vaccination such as meningococcal C conjugate (MCC) vaccine in national routine immunization schedules by the European Center for Disease Prevention and Control to treat meningitis is likely to drive the meningococcal infections treatment market in Europe. Rise in demand for vaccination is expected to propel the meningococcal infections treatment market in Asia Pacific. Increase in awareness about meningitis immunization and high prevalence of bacterial meningitis are likely to augment the global meningococcal infections treatment market in Middle East & Africa during the forecast period.
Key players developing therapeutics for meningococcal infections therapeutics are GlaxoSmithKline, plc, Pfizer, Inc., Merck & Co., Inc., Sanofi Pasteur SA, Astellas Pharma Inc., CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Sciences Corporation, and Panacea Biotec among others.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.